Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole.
Department of Internal Medicine, Hospital Arquitecto Marcide, Ferrol, Spain. fjf-fernandez@terra.es
F J
FJ
Fernández-Fernández
P
P
Sesma
T
T
Caínzos-Romero
L
L
Ferreira-González
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015738:Famotidine / Q000008:administration & dosage*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage; D006801:Humans; D008275:Magnesium Deficiency / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D009853:Omeprazole / Q000009:adverse effects*; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D015738:Famotidine; D000077402:Pantoprazole; D009853:Omeprazole